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Background: This study aimed to evaluate and compare the rel-
ative frequency, distribution, sites of presentation, and radiologi-
cal and histological variations of odontogenic cysts, tumours, and
tumour-like lesions in cases reported to the Government Dental
College, Trivandrum, India.
Methods: A retrospective analysis was done on 3222 biopsy
cases reported to the Department of Oral Medicine and Radiology
from January, 2000, to May, 2009. Biopsy records were also evalu-
ated from the Department of Oral Medicine and Department of
Oral Pathology and Microbiology.
Findings: Of 3222 biopsy cases reported, 1082 were diagnosed as
odontogenic cysts and tumours, and tumour-like lesionsof the jaw.
Of the 1082 cases, the highest frequencies were as follows: cyst of
inflammatory origin (periapical and radicular cyst; n = 589,
54.4%); ameloblastoma (n = 141, 13.03%); dentigerous cyst (n = 98,
9.05%); keratinising odontogenic tumour (n = 74, 6%); fibrous dys-
plasia (n = 25, 2%; females = 19, 75%; males = 6, 24%); dentigerous
cyst showing ameloblastoma transformation (n = 24, 2%); eruption
cyst (n = 55, 5%); osteoma (n = 22, 2%); central ossifying fibroma
(n = 20, 1.8%; females = 13, 65%; males = 7, 35%); odontome
(n = 16, 1.4%); adenomatoid odontogenic tumour (n = 6, 0.5%); cen-
tral giant-cell granuloma (n = 9, 0.8%); central odontogenic fibroma
(n = 6, 0.5%); cementoblastoma (n = 8, 0.8%); Pindborg tumour
(n = 5, 0.4%); and benign fibrous histiocytoma (n = 3, 0.2%). Rarer
conditions,which accounted for less than 0.2% of cases, were juve-
nile ossifying fibroma, ameloblastic fibrodontoma, chondrosar-
coma, central odontogenic myxoma, and plasma-cell myeloma.
Interpretation: The relative frequencies and sites of presenta-
tion of odontogenic cysts, tumours, and tumour-like lesions of
the jaw in different geographic backgrounds are essential for
early diagnosis and management of these potentially destructive
benign lesions.
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Background: In the oncology setting, specialist multidisciplin-
ary teams are often needed to ensure that patients receive the
best possible care and treatment. As drug experts, pharmacists
manage chemotherapy-related and supportive care issues. They
can also help to manage treatment costs and facilitate accurate
prescribing to maximise patient safety. Documentation of inter-
ventions done by pharmacists on ward rounds can be clinically
and educationally useful for improving prescribing safety and
pharmacy services. This study evaluated the impact of interven-
tions made by pharmacists on lymphoma ward rounds.
Methods: This was a cross-sectional analysis of interventions
made by pharmacists on the lymphoma service from 2009 to
2010, at Singapore General Hospital, where pharmacists from the
National Cancer Centre Singapore join lymphoma ward rounds 5
days a week. Interventions were documented in a database and
were given an impact rating by two independent reviewers – a lym-
phoma oncologist and an oncology pharmacist. Interventions
were classified into four impact levels and assessed as drug-
related, cost-related, or workflow issues. Spearmans correlation
test was used to test for agreement between the two reviewers.
Findings: A total of 295 interventions were made for 116
patients; 97% were accepted by oncologists. Most interventions
were related to antimicrobial dosing or usage (35%) and chemo-
therapy-related issues (29%). 23% of impact ratings were level 3
or 4. Ratings of interventions that helped to avoid or solve drug-
related problems and improve workflow were moderately concor-
dant between the two reviewers, in the areas of supportive care
(p = 0.544) and chemotherapy-related issues (p = 0.559). Overall,
the oncologist gave higher ratings for cost-saving interventions
and the pharmacist gave higher ratings for interventions that
help to avoid or resolve drug-related problems and improve
workflow.
Interpretation: Interventions by oncology pharmacists are well-
accepted onward rounds andhave a positive effect on patient care.
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Background: The MAGE-A3 tumour-specific antigen is
expressed by many tumours, including hepatocellular carcinoma
(HCC), and is therefore an appropriate target for active immuno-
therapy. Here, we report results from a retrospective epidemiolog-
ical evaluation of MAGE-A3 gene expression in Asian patients
with pathologically proven HCC, and its prognostic value.
Methods: 200 samples were analysed from two centres in Thai-
land and one in Taiwan. Patient and tumour characteristics were
also collected. Formalin-fixed paraffin-embedded (FFPE) tumour
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